OncoMatch/Clinical Trials/NCT06890858
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
Is NCT06890858 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fasudil Hydrochloride for ovarian cancer.
Treatment: Fasudil Hydrochloride — This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to immunotherapy in non-small cell lung cancer (NSCLC) and other tumors. The study plans to enroll 20 patients with A/A genotype ovarian cancer for treatment evaluation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Prior therapy
Must have received: platinum-based chemotherapy
After platinum based chemotherapy at Zhejiang Provincial People's Hospital
Lab requirements
Liver function
Patients with abnormal liver function [excluded]
Patients with abnormal liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify